---
title: "Moody’s upgrades Teva to investment-grade Baa3 rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295533397.md"
description: "Moody’s upgraded Teva Pharmaceutical Industries Ltd.’s corporate credit rating to investment-grade Baa3 from Ba1, with a stable outlook. The agency cited earnings-driven debt reduction, improving margins, solid free cash flow, and revenue diversity as key factors. Moody’s anticipates further debt reduction over the next 12 to 18 months."
datetime: "2026-08-11T12:03:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295533397.md)
  - [en](https://longbridge.com/en/news/295533397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295533397.md)
---

# Moody’s upgrades Teva to investment-grade Baa3 rating

-   Moody’s upgraded Teva’s corporate credit rating to Baa3 from Ba1, lifting it to investment grade with a stable outlook. \* Moody’s cited earnings-led debt reduction, improving margins, solid free cash flow, revenue diversity. \* Agency expects further debt reduction over the next 12 to 18 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800OMX\_\_\_\_\_CNEWS\_EN\_GNW1001257062\_en) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [MCO.US](https://longbridge.com/en/quote/MCO.US.md)

## Related News & Research

- [FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review](https://longbridge.com/en/news/296355997.md)
- [Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28](https://longbridge.com/en/news/296394259.md)
- [Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?](https://longbridge.com/en/news/296006711.md)
- [Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036](https://longbridge.com/en/news/296394736.md)
- [Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug](https://longbridge.com/en/news/296500759.md)